Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zhejiang Medicine CoSHSE:600216 +1.63%76 EV-to-EBITDA is 12.21 as of Aug. 26, 2026, which is 31% below its 10-year median of 17.61. GuruFocus rates SHSE:600216 with a GF Score™ of 76/100 and a GF Value™ of ¥13.93 (Fairly Valued). The stock has 6 warning signs investors should review. Among 735 Drug Manufacturers companies, Zhejiang Medicine Co ranks better than 52.52% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Zhejiang Medicine Co's enterprise value is ¥10,219 Mil.
Zhejiang Medicine Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was ¥837 Mil. Therefore, Zhejiang Medicine Co's EV-to-EBITDA for today is 12.21.
The historical rank and industry rank for Zhejiang Medicine Co's EV-to-EBITDA or its related term are showing as below:
SHSE:600216'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.55 Med: 17.61 Max: 144.07
Current: 12.21
During the past 13 years, the highest EV-to-EBITDA of Zhejiang Medicine Co was 144.07. The lowest was 6.55. And the median was 17.61.
SHSE:600216's EV-to-EBITDA is ranked better than 52.52% of 735
companies
in the Drug Manufacturers industry
Industry Median: 13.07
vs SHSE:600216: 12.21
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Zhejiang Medicine Co (SHSE:600216) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Zhejiang Medicine Co's PE Ratio (TTM) for today is calculated as:
Zhejiang Medicine Co's share price for today is ¥13.08.
Zhejiang Medicine Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.780.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Zhejiang Medicine Co's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Zhejiang Medicine Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhejiang Medicine Co EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zhejiang Medicine Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Zhejiang Medicine Co's EV-to-EBITDA falls into.
Zhejiang Medicine Co's current Enterprise Value is ¥10,219 Mil.
Zhejiang Medicine Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥837 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhejiang Medicine Co (SHSE:600216) has a EV-to-EBITDA of 12.21 as of Aug. 26, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Zhejiang Medicine Co. This is 31% below median its historical median of 17.61. Over the past decade, Zhejiang Medicine Co's EV-to-EBITDA has ranged from 6.55 to 144.07. According to the industry distribution chart, Zhejiang Medicine Co ranks #349 out of 735 companies in the Drug Manufacturers industry, placing it in the top 47.5%.
Is Zhejiang Medicine Co's EV-to-EBITDA too high?
Zhejiang Medicine Co's current EV-to-EBITDA of 12.21 is 31% below median its 10-year median of 17.61. Over the past 10 years, this metric has ranged from a low of 6.55 to a high of 144.07. The Drug Manufacturers industry median EV-to-EBITDA is 13.07. Zhejiang Medicine Co's value of 12.21 is 6.6% below this industry median. Based on the distribution chart, Zhejiang Medicine Co ranks #349 out of 735 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Zhejiang Medicine Co has a GF Score™ of 76/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Zhejiang Medicine Co's EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Zhejiang Medicine Co ranks #349 out of 735 companies for EV-to-EBITDA. This puts Zhejiang Medicine Co in the upper half of its industry. The industry median EV-to-EBITDA is 13.07. Zhejiang Medicine Co's value of 12.21 is 6.6% below this benchmark. Historically, Zhejiang Medicine Co's own EV-to-EBITDA has ranged from 6.55 to 144.07 over the past decade. While the company's 10-year median is 17.61 vs. the industry median of 13.07, Zhejiang Medicine Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.07, based on 735 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zhejiang Medicine Co's current EV-to-EBITDA of 12.21 is 6.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Zhejiang Medicine Co. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zhejiang Medicine Co's current EV-to-EBITDA is 12.21, which is 31% below median its own 10-year median of 17.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang Medicine Co stock overvalued right now?
Based on GuruFocus' analysis, Zhejiang Medicine Co (SHSE:600216) is currently considered Fairly Valued. The stock's GF Value™ is ¥13.93, compared to a current price of ¥13.08 — trading 6.1% below its estimated fair value. The current EV-to-EBITDA is 12.21, which is 31% below median its 10-year median of 17.61 and 6.6% below the Drug Manufacturers industry median of 13.07. Zhejiang Medicine Co's overall GF Score™ is 76/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Zhejiang Medicine Co (SHSE:600216), the current EV-to-EBITDA is 12.21 as of Aug. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zhejiang Medicine Co (SHSE:600216) Overvalued in 2026?
Based on GuruFocus' analysis, Zhejiang Medicine Co stock appears to be undervalued.
The current stock price of ¥13.08 is trading 6.1% below its estimated GF Value™ of ¥13.93.
GuruFocus considers Zhejiang Medicine Co to be Fairly Valued.
Key valuation signals for SHSE:600216:
EV-to-EBITDA: 12.21 (31% below median its 10-year median of 17.61)
GF Value™: ¥13.93 vs. price of ¥13.08 (6.1% below fair value)
Industry Position: 6.6% below the Drug Manufacturers median (#349 of 735)
No single metric tells the full story. See the SHSE:600216 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zhejiang Medicine Co Ltd is a china-based pharmaceutical company. The company manufactures fat-soluble vitamins, vitamins, quinolones, and antibiotic-resistant antibiotics, vitamin E, natural vitamin E, beta-carotene, cantharidin, vancomycin hydrochloride, and teicoplanin.
76GF Score
Get the complete analysis for SHSE:600216
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600216 has been successfully added to your 
